Boehringer Ingelheim Announced That Spesolimab (Marketed As Spevigo) Received Breakthrough Therapy Designation (Btd) As An Investigational Treatment For The Prevention Of Flares In Adolescents And Adults With Generalized Pustular Psoriasis (Gpp) From The Us Food And Drug Administration (Fda).
